Boston Scientific has launched its Promus Premier everolimus-eluting platinum chromium coronary stent system in Japan, and is the company’s next-generation durable polymer drug-eluting stent (DES).
The next-generation DES system recently received Japan Ministry of Health, Labor and Welfare (MHLW) approval.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
With extensive input from interventional cardiologists, the Promus Premier stent system is designed to provide physicians with improved DES performance in treating patients with coronary artery disease.
According to the company, the Promus Premier stent system features unparalleled visibility and low recoil, as well as exceptional radial strength and fracture-resistance.
It is reportedly the only platform to feature customised platinum chromium (PtCr) stent architecture, the market-leading everolimus drug coating and fluorinated co-polymer, and an enhanced low-profile delivery system.
Boston Scientific Japan president and representative director Yusuke Naiki said: “This innovative stent enhances our portfolio of coronary intervention products, and we believe it will strengthen our position in Japan’s DES market.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCoronary artery disease (CAD) is the most common type of heart disease. It happens when arteries that supply blood to heart muscle become hardened and narrow.
Patients with CAD may experience pain, shortness of breath and fatigue. They may also be at risk for a heart attack.
Among several treatment options, one option is to place a stent in the artery to help keep it open and allow the blood to flow more freely.
Boston Scientific president interventional cardiology Kevin Ballinger said the Promus Premier stent system reflects company’s commitment to DES technology.
“Japan is an important interventional cardiology market, and we believe the launch and success of this stent system in Japan will enhance Boston Scientific’s overall growth strategy in the DES market,” Ballinger added.
The company obtained CE Mark and the US Food and Drug Administration approvals for the Promus Premier stent system in February and November of 2013, respectively.
Image: Boston Scientific receives FDA approval for the Promus Premier everolimus-eluting platinum chromium coronary stent system. Photo: courtesy of Boston Scientific Corporation.
